M7824 (Anti-PD-L1/TGF-Beta TRAP) in a Window Setting in Patients With Stage II-III HER2/Neu Positive (HER2+) Breast Cancer (BC)
Condition: Malignant Neoplasm of Breast Interventions: Drug: M7824 - patients with Stage II or III HER2+ breast cancer; Drug: Chemotherapy Sponsors: M.D. Anderson Cancer Center; EMD Serono Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials